Teva Gains Global Rights to Polpharma Biologics Ocrevus Biosimilar
Licensing deal pairs Israeli pharma company's commercial reach with Swiss firm's biosimilar development capabilities for multiple sclerosis treatment
Teva Pharmaceutical Industries Ltd has secured exclusive global commercialization rights to a proposed biosimilar candidate to Ocrevus (ocrelizumab) through a licensing agreement with Polpharma Biologics International AG, pending regulatory approval.
Under the terms of the deal announced July 9, Teva Pharmaceuticals International GmbH, a subsidiary of the Tel Aviv-based Teva, will commercialize both formulations of the Polpharma Biologics biosimilar upon clearance. The arrangement pairs the Swiss biologics company's track record in biosimilar development with Teva's commercial infrastructure and market access capabilities.
Ocrevus, a Roche-developed B-cell depleting therapy, represents a major revenue opportunity in multiple sclerosis treatment. The biosimilar space has become increasingly competitive as patents on blockbuster biologics expire, with companies seeking to capture market share through approved alternatives. Teva's portfolio has traditionally leaned on generic medications, making this agreement a continuation of the company's pivot toward specialty pharmaceuticals and biologics.
Polpharma Biologics has established itself as a developer of biosimilar candidates, and the partnership with Teva signals confidence in advancing the Ocrevus biosimilar through global regulatory pathways. Teva's established distribution channels and relationships with payers position it to move quickly on commercialization once approvals are secured.
The deal underscores the economics driving biosimilar development: as blockbuster biologics face patent cliffs, manufacturers gain incentive to invest in copycat versions that can command substantial discounts while generating meaningful revenue. For Teva, the agreement represents another avenue to offset margin pressure in its core generics business and expand its foothold in higher-margin specialty markets.
Neither party disclosed financial terms of the agreement. The success of the partnership will depend on the timing and breadth of regulatory approvals across key markets, particularly in the United States and Europe.